You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 10/20/2014

Company Name Symbol %Change
ONCOLYTICS B ONCY
19.07%
DEJOUR ENERG DEJ
11.80%
POST HOLDING POST
8.90%
SUNEDISON IN SUNE
7.70%
GW PHARMACEU GWPH
7.14%
Pancreatic Cancer - Pipeline Review, H2 2012

Print Share

Dec 10, 2012 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/q8pp3z/pancreatic_cancer) has announced the addition of Global Markets Direct's new report "Pancreatic Cancer - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. Pancreatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Pancreatic Cancer. - A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pancreatic Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Pancreatic Cancer Therapeutics Development Include: - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi-Aventis - AstraZeneca PLC - Eli Lilly and Company - Viralytics Ltd. - GlaxoSmithKline plc - Tekmira Pharmaceuticals Corp. - Genentech, Inc. - Biotest AG - AbGenomics International, Inc. - Oxford BioMedica plc - Infinity Pharmaceuticals, Inc. - YM BioSciences Inc. - FibroGen, Inc. - Light Sciences Oncology, Inc. - Piramal Healthcare Limited - MediGene AG And many more... For more information visit http://www.researchandmarkets.com/research/q8pp3z/pancreatic_cancer Source: Global Markets Direct

CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Oncology (http://www.researchandmarkets.com/categories.asp?cat_id=122&campaign_id=q8pp3z)

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

(C)1994-2012 M2 COMMUNICATIONS

**********************************************************************

As of Thursday, 12-06-2012 23:59, the latest Comtex SmarTrendA? Alert,
an automated pattern recognition system, indicated a DOWNTREND on
02-15-2012 for AZN @ $45.43.

As of Thursday, 12-06-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated an UPTREND on
03-13-2012 for BMY @ $33.26.

As of Thursday, 12-06-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated a DOWNTREND on
05-17-2012 for GSK @ $44.67.

For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright A? 2004-2012 Comtex News Network, Inc. All rights reserved.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.